CN111529135A - Acetabular cup and acetabular prosthesis system - Google Patents

Abstract

The application provides an acetabular cup and an acetabular prosthesis system, and relates to the technical field of medical devices. The acetabular cup includes a first matrix and a first porous layer. The first porous layer has a plurality of uniformly distributed and interconnected pores. The first porous layer is loaded with a bone growth promoting drug and an antibacterial and anti-inflammatory drug, wherein the bone growth promoting drug is filled in the inner layer of the first porous layer, and the antibacterial and anti-inflammatory drug is filled in the outer layer of the first porous layer. The sustained-release drug loaded in the first porous layer can be continuously administered after the acetabular cup is implanted into the human body, and the antibacterial and anti-inflammatory drugs filled in the outer layer of the first porous layer at the initial stage of implantation are slowly released To achieve antibacterial and anti-inflammatory to prevent infection, after the initial combination of the acetabular cup and human bone tissue, the bone growth-promoting drug filled in the inner layer of the first porous layer is slowly released to promote bone growth for a long time, so that the human body and the transplanted The fusion degree and fusion efficiency of the acetabular cup are improved.

Description

An acetabular cup and acetabular prosthesis system

technical field

The present application relates to the technical field of medical devices, and in particular, to an acetabular cup and an acetabular prosthesis system.

Background technique

When a tumor occurs around the acetabulum, surgical resection is required, resulting in a large bone loss in the acetabulum, thereby interrupting the continuity of the pelvis and losing part of the surrounding soft tissue, so the missing pelvis needs to be reconstructed .

In recent years, more and more acetabular cup prostheses have been transplanted into the missing pelvis for pelvic repair, but the human body is resistant to foreign implants, resulting in low fusion efficiency. Also, infection is inevitable during the transplant process.

SUMMARY OF THE INVENTION

The purpose of the embodiments of the present application is to provide an acetabular cup and an acetabular prosthesis system, which can improve the technical problems of low transplantation efficiency and high infection rate of the acetabular cup prosthesis.

In a first aspect, embodiments of the present application provide an acetabular cup, which includes a first base body and a first porous layer, and part or all of the surface of the first base body is covered with the first porous layer.

The first porous layer has a plurality of pores that are evenly distributed and communicated with each other.

The first porous layer is loaded with a bone growth promoting drug and an antibacterial and anti-inflammatory drug, wherein the bone growth promoting drug is filled in the inner layer of the first porous layer, and the antibacterial and anti-inflammatory drug is filled in the outer layer of the first porous layer.

In the above implementation process, the acetabular cup provided by the present application includes a first porous layer disposed on the surface of the first substrate, the first porous layer can be loaded with a sustained-release drug, and the sustained-release drug loaded in the first porous layer The drug can be administered continuously after the acetabular cup is implanted in the body.

In the initial stage of implantation, the antibacterial and anti-inflammatory drugs filled in the outer layer of the first porous layer are slowly released to achieve antibacterial and anti-inflammatory prevention to prevent infection. After the acetabular cup is initially combined with human bone tissue, the inner layer filled in the first porous layer promotes The slow release of bone growth drugs is used to promote bone growth over a longer period of time, resulting in improved fusion and fusion efficiency between the human body and the implanted acetabular cup.

In a possible embodiment, the surface of the first porous layer is coated with antibacterial and anti-inflammatory drugs.

In one possible embodiment, the bone growth promoting drug comprises bone morphogenetic protein BMP, fibroblast growth factor FGF or transforming growth factor TGF-B.

In the above realization process, bone growth promoting drugs such as bone morphogenetic protein BMP, fibroblast growth factor FGF or transforming growth factor TGF-β can be filled in the inner layer of the first porous layer. The drug is released slowly and promotes bone growth over an extended period of time.

In a possible embodiment, the antibacterial and anti-inflammatory drugs include penicillin, cephalosporin or aspirin.

In the above implementation process, antibacterial and anti-inflammatory drugs such as penicillin, cephalosporin or aspirin can be filled in the outer layer of the first porous layer, and after the acetabular cup is transplanted, the above drugs can be slowly released to achieve antibacterial, anti-inflammatory and prevent infection .

In a possible embodiment, the porosity of the first porous layer is 86-90%, and the cross-sectional diameter of the holes is 200-1200 μm.

In the above realization process, the first porous layer with a porosity of 86-90% is similar to the host bone tissue, which can improve the bonding strength of the interface between the acetabular cup and the host bone tissue, so that the acetabular cup and the host bone tissue can achieve deep fusion .

In a possible embodiment, the material of the first porous layer is titanium alloy or simple titanium, and the surface roughness of the first porous layer is 2-9 μm.

In the above realization process, porous titanium is a good biomimetic material, which has good biocompatibility, excellent biomechanics, and elastic modulus close to bone tissue.

In a second aspect, embodiments of the present application provide an acetabular prosthesis system, which includes an augmenting member and the above-mentioned acetabular cup, the acetabular cup has a first curved surface, the augmenting member has a second curved surface, and the augmenting member and the hip The cup is matched and connected with the second curved surface through the first curved surface.

In the above implementation, the augmentation member is used to fill the cavity formed by the removed damaged or surgically removed acetabulum.

The present application makes the acetabular cup prosthesis system better conform to the shape of the host bone tissue through the cooperation of the acetabular cup and the augmenting member. In addition, the sustained-release drug loaded by the acetabular cup prosthesis system through the first porous layer of the acetabular cup is continuously administered after being implanted into the human body, so as to prevent infection after the acetabular cup prosthesis system is implanted, and improve the relationship between the human body and the human body. Fusion and fusion efficiency of implanted acetabular cup prosthetic systems.

In a possible embodiment, the enlargement member includes a second base body and a second porous layer, a part or all of the surface of the second base body is covered with the second porous layer, and the second porous layer has a plurality of uniform distributions and interconnected pores.

In the above implementation process, the augmenting member also has a second porous layer. The second porous layer is similar to the host bone tissue, which can improve the bonding strength of the interface between the augmenting member and the host bone tissue. achieve deep integration.

In a possible embodiment, the second porous layer is loaded with a bone growth-promoting drug and an antibacterial and anti-inflammatory drug, wherein the bone growth-promoting drug is filled in the inner layer of the second porous layer, and the antibacterial and anti-inflammatory drug is filled in the second porous layer. the outer layer of the layer.

In the above implementation process, the second porous layer can also be used as a carrier, loaded with drugs for promoting bone growth and antibacterial and anti-inflammatory drugs, and the antibacterial and anti-inflammatory drugs filled in the outer layer of the second porous layer at the initial stage of implantation are slowly released to achieve antibacterial and anti-inflammatory drugs. To prevent infection, after the initial combination of the enlargement member and the human bone tissue, the bone growth-promoting drug filled in the inner layer of the second porous layer is slowly released to promote bone growth for a long time, so that the enlargement of the human body and the transplant can be achieved. The fusion degree and fusion efficiency of the components are improved.

In a possible embodiment, the surface of the second porous layer is coated with antibacterial and anti-inflammatory drugs.

Description of drawings

In order to illustrate the technical solutions of the embodiments of the present application more clearly, the following drawings will briefly introduce the drawings that need to be used in the embodiments. It should be understood that the following drawings only show some embodiments of the present application, and therefore do not It should be regarded as a limitation of the scope, and for those of ordinary skill in the art, other related drawings can also be obtained according to these drawings without any creative effort.

Fig. 1 is the structural representation of the acetabular cup of the embodiment of the application;

Fig. 2 is the sectional view of the acetabular cup of the embodiment of the application;

3 is a schematic diagram of the first filling structure of the sustained-release drug in the first porous layer according to the embodiment of the application;

4 is a schematic diagram of the second filling structure of the sustained-release drug in the first porous layer according to the embodiment of the application;

5 is a schematic diagram of the third filling structure of the sustained-release drug in the first porous layer according to the embodiment of the application;

6 is a schematic diagram of the fourth filling structure of the sustained-release drug in the first porous layer according to the embodiment of the application;

7 is a schematic diagram of the fifth filling structure of the sustained-release drug in the first porous layer according to the embodiment of the application;

8 is a schematic structural diagram of an unconnected acetabular prosthesis system according to an embodiment of the application;

FIG. 9 is a schematic structural diagram of an acetabular prosthesis system according to an embodiment of the application after being connected;

FIG. 10 is a cross-sectional view of an enlarged member according to an embodiment of the application.

Icon: 10-acetabular prosthesis system; 100-acetabular cup; 101-first curved surface; 102-connecting hole; 110-first matrix; 120-first porous layer; 130-antibacterial and anti-inflammatory drug; 140-promoting 200-enlargement member; 201-second curved surface; 210-second matrix; 220-second porous layer; 300-screw.

Detailed ways

In order to make the purposes, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be described clearly and completely below with reference to the drawings in the embodiments of the present application. Obviously, the described embodiments It is a part of the embodiments of the present application, but not all of the embodiments. The components of the embodiments of the present application generally described and illustrated in the drawings herein may be arranged and designed in a variety of different configurations.

Thus, the following detailed description of the embodiments of the application provided in the accompanying drawings is not intended to limit the scope of the application as claimed, but is merely representative of selected embodiments of the application. Based on the embodiments in the present application, all other embodiments obtained by those of ordinary skill in the art without creative work fall within the protection scope of the present application.

It should be noted that like numerals and letters refer to like items in the following figures, so once an item is defined in one figure, it does not require further definition and explanation in subsequent figures.

In the description of this application, it should be noted that the orientation or positional relationship indicated by the terms "inside", "outside", etc. is based on the orientation or positional relationship shown in the accompanying drawings, or is usually placed when the product of the application is used. The orientation or positional relationship is only for the convenience of describing the present application and simplifying the description, rather than indicating or implying that the indicated device or element must have a specific orientation, be constructed and operated in a specific orientation, and therefore should not be construed as a limitation on the present application. Furthermore, the terms "first", "second", etc. are only used to differentiate the description and should not be construed to indicate or imply relative importance.

In the description of this application, it should also be noted that, unless otherwise expressly specified and limited, the terms "arrangement" and "connection" should be understood in a broad sense, for example, it may be a fixed connection or a detachable connection, or Integrally connected; either mechanical or electrical. For those of ordinary skill in the art, the specific meanings of the above terms in this application can be understood in specific situations.

Referring to FIGS. 1-2 , an embodiment of the present application provides an acetabular cup 100 , which includes a first base body 110 and a first porous layer 120 , and part or all of the surface of the first base body 110 is covered with the first porous layer 120.

In the embodiment shown in FIGS. 1-2 , the first porous layer 120 completely wraps the first substrate 110 , that is, the entire surface of the first substrate 110 is covered with the first porous layer 120 . In some other embodiments of the present application, only the surface of the acetabular cup 100 combined with the host bone tissue may be covered with the first porous layer 120 , and the edge portion of the first base body 110 may not be covered with the first porous layer 120 . Aperture layer 120 .

The first porous layer 120 has a plurality of irregular-shaped pores uniformly distributed in the interior and the surface. Irregular-shaped holes distributed in the interior and surface of the first porous layer 120 are connected with each other to form a biomimetic transport channel.

The porosity of the first porous layer 120 is 86-90%, the cross-sectional diameter of the holes is 200-1200 μm, and the depth of the holes is >1500 μm.

In the embodiment shown in FIGS. 1-2 , the porosity of the first porous layer 120 is 88%, the cross-sectional diameter of the holes is 200-1200 μm, and the depth of the holes is >1500 μm. In some other embodiments of the present application, the porosity of the first porous layer 120 may also be 86%, 87%, 89% or 90%, and the cross-sectional pore size of the holes in the first porous layer 120 may also be 300-800 μm , 500～1000μm, 700～900μm, 400～700μm or 700～1000μm, the depth of the hole can also be >1600μm, >1650μm or >1850μm.

The first porous layer 120 has a trabecular bone-like structure, and the porous structure can be used to load sustained-release drugs, thereby improving the load capacity of the acetabular cup 100 . At the same time, in the present application, by adjusting the pore structure of the first porous layer 120, including the porosity, the cross-sectional diameter of the pore, and the depth of the pore, the elastic modulus of the first porous layer 120 is close to the bone tissue, and has good biocompatibility. , the bonding strength of the interface between the acetabular cup 100 and the host bone tissue can be improved, so that the acetabular cup 100 and the host bone tissue can be deeply fused.

The first base body 110 is made of metal.

In the embodiment shown in FIGS. 1-2 , the first base body 110 is made of titanium alloy. In some other embodiments of the present application, the first base body 110 may also be made of other metal materials, such as silver element, iron alloy, titanium element, and the like.

The first porous layer 120 is made of titanium element or titanium alloy, and the surface roughness of the first porous layer 120 is 2-9 μm.

In the embodiments shown in FIGS. 1-2 , the first porous layer 120 is made of titanium powder by 3D printing technology, and its surface roughness is 3-6 μm. In some other embodiments of the present application, the first porous layer 120 can also be produced by a technology capable of producing a porous structure, and the surface roughness of the first porous layer 120 can also be 2-6 μm, 3-7 μm, 4-8 μm, 5-9 μm , 2～8μm or 3～9μm.

It should be noted that the infiltration response of the porous titanium surface layer structure in the examples of the present application is beneficial to the functional synthesis of the components in the blood to imitate bone tissue.

Please refer to FIGS. 3 to 7 , the first porous layer 120 is loaded with the bone growth-promoting drug 140 and the antibacterial and anti-inflammatory drug 130 , wherein the bone growth-promoting drug 140 is filled in the inner layer of the first porous layer 120 , and the antibacterial and anti-inflammatory drug 130 is filled in the inner layer of the first porous layer 120 . The outer layer of the first porous layer 120 .

It should be noted that the inner layer and the outer layer of the first porous layer 120 in the embodiment of the present application are opposite, and the drug filled in the outer layer of the first porous layer 120 can be released relatively quickly after the implantation of the prosthesis out, and the drug filled in the inner layer of the first porous layer 120 can be released for a longer period of time after implantation of the prosthesis.

Therefore, the antibacterial and anti-inflammatory drugs 130 filled in the outer layer of the first porous layer 120 can be released within 3 to 4 weeks after the acetabular cup 100 is transplanted, that is, the antibacterial and anti-inflammatory drugs 130 can be used in the inflammation after the acetabular cup 100 is transplanted. The continuous administration during the elimination period achieves antibacterial and anti-inflammatory prevention of infection, so that the acetabular cup 100 is stable in the elimination period of excessive inflammation after transplantation. The bone growth-promoting drug 140 filled in the inner layer of the first porous layer 120 can be released half a year after the acetabular cup 100 is implanted, that is, the bone-growth-promoting drug 140 can last in the overall recovery period after the acetabular cup 100 is implanted The continuous administration achieves the promotion of bone growth, so that the fusion degree and fusion efficiency of the human body and the implanted acetabular cup 100 are improved.

In the embodiment of the present application, the amount of the antibacterial and anti-inflammatory drug 130 and the bone growth promoting drug 140 in the first porous layer 120 is adapted according to the slow release period and the filling speed of human bone tissue growth. For example, the amount of the antibacterial and anti-inflammatory drugs 130 filled in the first porous layer 120 can ensure a sustained release period of at least 3-4 weeks, and the amount of the bone growth promoting drugs 140 filled in the first porous layer 120 can be guaranteed to be at least 3-4 weeks. A six-month slow-release cycle.

The antibacterial and anti-inflammatory drugs 130 and the bone growth promoting drugs 140 in the first porous layer 120 can be filled as follows:

In the embodiment shown in FIG. 3 , the thickness of the antibacterial and anti-inflammatory drugs 130 and the bone growth-promoting drugs 140 in the first porous layer 120 may be equal, and the antibacterial and anti-inflammatory drugs 130 and the bone-growth-promoting drugs 140 do not overlap each other and fill the entire The pores of the first porous layer 120 .

In the embodiment shown in FIG. 4 , the thicknesses of the antibacterial and anti-inflammatory drugs 130 and the bone-growth-promoting drugs 140 in the first porous layer 120 are not equal, and the thickness of the bone-growth-promoting drugs 140 is greater than that of the antibacterial and anti-inflammatory drugs 130 . thickness, and the antibacterial and anti-inflammatory drug 130 and the bone growth-promoting drug 140 do not overlap each other and fill the entire hole of the first porous layer 120 .

In the embodiment shown in FIG. 5 , the thicknesses of the antibacterial and anti-inflammatory drugs 130 and the bone growth-promoting drugs 140 in the first porous layer 120 are not equal, and the thickness of the antibacterial and anti-inflammatory drugs 130 is greater than that of the bone-growth-promoting drugs 140 . thickness, and the antibacterial and anti-inflammatory drug 130 and the bone growth-promoting drug 140 do not overlap each other and fill the entire hole of the first porous layer 120 .

In the embodiment shown in FIG. 6 , the thicknesses of the antibacterial and anti-inflammatory drugs 130 and the bone growth-promoting drugs 140 in the first porous layer 120 may be equal, and the antibacterial and anti-inflammatory drugs 130 and the bone-growth-promoting drugs 140 are overlapped and filled in the middle part. Holes throughout the first porous layer 120 .

In the embodiment shown in FIG. 7 , the thicknesses of the antibacterial and anti-inflammatory drugs 130 and the bone growth-promoting drugs 140 in the first porous layer 120 may be equal, and the antibacterial and anti-inflammatory drugs 130 and the bone-growth-promoting drugs 140 do not overlap with each other nor do they Filling the entire pores of the first porous layer 120 .

In some other embodiments of the present application, the thicknesses of the antibacterial and anti-inflammatory drugs 130 and the bone growth-promoting drugs 140 in the first porous layer 120 may not be equal, and the antibacterial and anti-inflammatory drugs 130 and the bone growth-promoting drugs 140 overlap each other in the middle and fill the entire The pores of the first porous layer 120 . Or the antibacterial and anti-inflammatory drugs 130 and the bone growth-promoting drugs 140 in the first porous layer 120 may be filled with different thicknesses, and the antibacterial and anti-inflammatory drugs 130 and the bone-growth-promoting drugs 140 do not overlap each other nor fill the entire first porous layer 120 . holes.

It should be noted that the present application does not limit the types of antibacterial and anti-inflammatory drugs 130 and bone growth-promoting drugs 140, as long as they can exert antibacterial and anti-inflammatory effects and promote bone growth, and are harmless to the human body.

In the embodiments of the present application, the antibacterial and anti-inflammatory drugs 130 include penicillins, cephalosporins, tetracyclines, chloramphenicol, macrolides, lincomycin, fluoroquinolones, nitroimidazoles, polypeptides and quaternary ammonium antibacterial and anti-inflammatory drugs130 and aspirin, p-indomethacin, naproxen, diclofenac, ibuprofen, nimesulide, celecoxib antibacterial and anti-inflammatory drugs130; One or more of morphogenetic protein BMP, fibroblast growth factor FGF, transforming growth factor TGF-β and insulin-like growth factor IGF.

The antibacterial and anti-inflammatory drugs 130 and the bone growth promoting drugs 140 are filled in the holes of the first porous layer 120 by embedding or coating.

When the coating method is adopted, a part of the antibacterial and anti-inflammatory drug 130 may be finally coated on the surface of the first porous layer 120, and part of the coated antibacterial and anti-inflammatory drug 130 sinks into the inner surface of the first porous layer 120 due to the action of gravity. In the holes, other antibacterial and anti-inflammatory drugs 130 are distributed on the surface of the first porous layer 120 .

The antibacterial and anti-inflammatory drug 130 coated on the surface of the first porous layer 120 can act directly and take effect quickly, and can play a better antibacterial and anti-inflammatory effect on the newly transplanted acetabular cup 100 .

Referring to Figures 8-9, the present application provides an acetabular prosthesis system 10 comprising an augmenting member 200 for filling a cavity formed by a removed damaged or surgically removed acetabulum and the aforementioned In the acetabular cup 100 , the acetabular cup 100 has a first curved surface 101 , the augmenting member 200 has a second curved surface 201 , and the augmenting member 200 and the acetabular cup 100 are connected to each other through the first curved surface 101 and the second curved surface 201 .

In the embodiment shown in FIGS. 8-9 , the acetabular prosthesis system 10 further includes a screw 300 , the acetabular cup 100 and the augmenting member 200 both have connecting holes 102 that pass through and cooperate with each other, and the screw 300 is in turn of the acetabulum The connecting hole 102 of the cup 100 and the connecting hole 102 of the augmenting member 200 are finally fixed on the human bone tissue, so that the acetabular cup 100 and the augmenting member 200 are stably connected.

The enlarged member 200 includes a second base body 210 and a second porous layer 220 , and a part or all of the surface of the second base body 210 is covered with the second porous layer 220 .

In the embodiments shown in FIGS. 8 to 10 , the second porous layer 220 completely wraps the second substrate 210 , that is, the entire surface of the second substrate 210 is covered with the second porous layer 220 . In some other embodiments of the present application, the second porous layer 220 may be covered only on the surface of the augmenting member 200 combined with the host bone tissue, and the edge portion of the second base 210 may not be covered with the second porous layer 220 . Aperture layer 220 .

The second porous layer 220 is similar in structure to the first porous layer 120, and also has a plurality of irregular-shaped pores evenly distributed in the interior and the surface. The irregular-shaped holes distributed in the interior and surface of the second porous layer 220 are connected with each other to form a biomimetic transport channel.

The porosity of the second porous layer 220 is 86-90%, and the porosity of the second porous layer 220 is 86-90%.

In the embodiment shown in FIG. 10 , the porosity of the second porous layer 220 is 88%, the cross-sectional diameter of the holes is 200-1200 μm, and the depth of the holes is >1500 μm. In some other embodiments of the present application, the porosity of the second porous layer 220 may also be 86%, 87%, 89% or 90%, and the cross-sectional pore size of the holes in the second porous layer 220 may also be 400-800 μm , 500～9000μm, 200～900μm, 200～700μm or 300～1000μm, the depth of the hole can also be >1700μm, >1750μm or >1900μm.

The second porous layer 220 has a trabecular bone structure, which is similar to the host bone tissue, and can improve the bonding strength of the interface between the augmenting member 200 and the host bone tissue, so that the augmenting member 200 and the host bone tissue achieve deep fusion. In addition, the porous structure of the second porous layer 220 can be used to load the sustained-release drug, so as to improve the load capacity of the augmenting member 200 .

The second base body 210 is made of metal.

In the embodiment shown in FIG. 10 , the second base body 210 is made of titanium alloy. In some other embodiments of the present application, the second base body 210 may also be made of other metal materials, such as silver element, iron alloy, titanium element, and the like.

The second porous layer 220 is made of titanium element or titanium alloy, and the surface roughness of the second porous layer 220 is 2-9 μm.

In the embodiments shown in FIGS. 8-10 , the second porous layer 220 is made of titanium powder by 3D printing technology, and its surface roughness is 3-6 μm. In some other embodiments of the present application, the second porous layer 220 can also be produced by a technology capable of producing a porous structure, and the surface roughness of the second porous layer 220 can also be 2-5 μm, 3-5 μm, 4-7 μm, 4-9 μm , 3～8μm or 5～9μm.

Similarly, the second porous layer 220 can also be loaded with the bone growth-promoting drug 140 and the antibacterial and anti-inflammatory drug 130, wherein the bone growth-promoting drug 140 is filled in the inner layer of the second porous layer 220, and the antibacterial and anti-inflammatory drug 130 is filled in the second porous layer 220. The outer layer of the porous layer 220 .

In the embodiment of the present application, the amount of the antibacterial and anti-inflammatory drug 130 and the bone growth promoting drug 140 in the second porous layer 220 is adapted according to the slow release period and the filling speed of human bone tissue growth. The antibacterial and anti-inflammatory drugs 130 filled in the outer layer of the second porous layer 220 can be released within 3 to 4 weeks after the acetabular prosthesis system 10 is implanted, that is, the antibacterial and anti-inflammatory drugs 130 can be released after the acetabular prosthesis system 10 is implanted. The continuous administration of the inflammatory elimination period achieves antibacterial and anti-inflammatory prevention to prevent infection, so that the acetabular prosthesis system 10 is stable in the excessive inflammation elimination period after transplantation. The bone growth-promoting drug 140 filled in the inner layer of the second porous layer 220 can be released half a year after the acetabular prosthesis system 10 is implanted, that is, the bone-growth-promoting drug 140 can be released after the acetabular prosthesis system 10 is implanted. The continuous administration during the overall recovery period achieves the promotion of bone growth and improves the fusion degree and fusion efficiency of the human body and the implanted acetabular prosthesis system 10 .

The filling structure of the antibacterial and anti-inflammatory drug 130 and the bone growth promoting drug 140 in the second porous layer 220 is similar to that in the first porous layer 120 .

The antibacterial and anti-inflammatory drugs 130 and the bone growth promoting drugs 140 are filled in the holes of the second porous layer 220 by embedding or coating.

When the coating method is used, a part of the antibacterial and anti-inflammatory drug 130 may be finally coated on the surface of the second porous layer 220, and part of the coated antibacterial and anti-inflammatory drug 130 sinks into the inner surface of the second porous layer 220 due to gravity. In the holes, other antibacterial and anti-inflammatory drugs 130 are distributed on the surface of the second porous layer 220 .

The antibacterial and anti-inflammatory drugs 130 filled on the surface of the second porous layer 220 can act directly and take effect quickly, and can play a better antibacterial and anti-inflammatory effect on the newly transplanted acetabular prosthesis system 10 .

To sum up, an acetabular cup and an acetabular prosthesis system provided by the embodiments of the present application, the acetabular cup 100 includes a first base body 110 and a first porous layer 120 disposed on the surface of the first base body 110 . A porous layer 120 can be loaded with sustained-release drugs, and the sustained-release drugs loaded in the first porous layer 120 can be continuously administered after the acetabular cup 100 is implanted into the human body. The acetabular prosthesis system 10 includes the above-mentioned acetabular cup 100 and an augmentation member 200 . The augmentation member 200 includes a second base body 210 and a second porous layer 220 disposed on the surface of the second base body 210 . The second porous layer 220 The sustained-release drug can also be loaded, and the sustained-release drug loaded in the second porous layer 220 can be continuously administered after the augmentation member 200 is implanted into the human body. In addition, the amount of the antibacterial and anti-inflammatory drug 130 and the bone growth promoting drug 140 in the first porous layer 120 and the second porous layer 220 is adapted according to the slow release period and the filling speed of human bone tissue growth. The amount of antibacterial and anti-inflammatory drugs 130 filled in the first porous layer 120 and the second porous layer 220 can ensure a sustained release period of at least 3 to 4 weeks, and the amount of the antibacterial and anti-inflammatory drugs 130 filled in the first porous layer 120 and the second porous layer 220 can ensure a sustained release period of at least 3 to 4 weeks. The amount of the bone growth promoting drug 140 in the layer 220 can ensure a sustained release period of at least half a year.

The above descriptions are only preferred embodiments of the present application, and are not intended to limit the present application. For those skilled in the art, the present application may have various modifications and changes. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of this application shall be included within the protection scope of this application.

Claims (10)

1. An acetabular cup, characterized in that, the acetabular cup comprises a first substrate and a first porous layer, and a part of the surface or the entire surface of the first substrate is covered with the first porous layer; The first porous layer has a plurality of evenly distributed and interconnected pores; The first porous layer is loaded with a drug for promoting bone growth and an antibacterial and anti-inflammatory drug, wherein the drug for promoting bone growth is filled in the holes of the inner layer of the first porous layer, and the antibacterial and anti-inflammatory drug is filled in the in the pores of the outer layer of the first porous layer. 2 . The acetabular cup according to claim 1 , wherein the surface of the first porous layer is coated with the antibacterial and anti-inflammatory drug. 3 . 3. acetabular cup according to claim 1, is characterized in that, described bone growth promoting drug comprises bone morphogenetic protein BMP, fibroblast growth factor FGF or transforming growth factor TGF-B. 4 . The acetabular cup according to claim 1 , wherein the antibacterial and anti-inflammatory drugs include penicillin, cephalosporin or aspirin. 5 . 5 . The acetabular cup according to claim 1 , wherein the porosity of the first porous layer is 86-90%, and the cross-sectional diameter of the holes is 200-1200 μm. 6 . 6 . The acetabular cup according to claim 1 , wherein the material of the first porous layer is titanium alloy or simple titanium, and the surface roughness of the first porous layer is 2-9 μm. 7 . 7. An acetabular prosthesis system, characterized in that the acetabular prosthesis system comprises an augmenting member and the acetabular cup according to any one of claims 1 to 6, the acetabular cup having a first curved surface , the enlargement member has a second curved surface, and the enlargement member and the acetabular cup are connected with the second curved surface through the first curved surface. 8. The acetabular prosthesis system according to claim 7, wherein the augmenting member comprises a second base body and a second porous layer, and a part or all of the surface of the second base body is covered with the The second porous layer has a plurality of uniformly distributed and interconnected pores. 9. The acetabular prosthesis system of claim 8, wherein the second porous layer is loaded with the bone growth-promoting drug and the antibacterial and anti-inflammatory drug, wherein the bone-growth-promoting drug is filled in In the inner layer of the second porous layer, the antibacterial and anti-inflammatory drug is filled in the outer layer of the second porous layer. 10. The acetabular prosthesis system according to claim 9, wherein the surface of the second porous layer is coated with the antibacterial and anti-inflammatory drug.

Images